Complete resolution of primary myelofibrosis in an infant with steroids and hydroxyurea.
Sanjeev KheraPriyanka MisraKanwaljeet SinghPreeti TripathiPublished in: BMJ case reports (2023)
Paediatric primary myelofibrosis (PMF) is exceedingly rare and distinct compared with adult PMF. It is characterised by peripheral blood cytopenias, leucoerythroblastosis, reticulin fibrosis, extramedullary haematopoiesis and hepatosplenomegaly. In the absence of laid down diagnostic criteria, the diagnosis is largely of exclusion. Though early haematological stem cell transplant (HSCT) remains the treatment of choice, spontaneous remission or remission with steroids and/or cytoreductive agents is described in around 20% of cases of paediatric PMF. Moreover, HSCT in paediatric PMF is associated with high mortality (30%-45%). Therefore, it may be prudent to consider a trial of steroids and/or cytoreductive agents in all transfusion-dependent paediatric PMF while considering HSCT and ongoing bone marrow donor search. We describe one such infant with PMF who had complete remission of clinical and haematological parameters with a combination therapy of steroids and hydroxyurea.
Keyphrases
- combination therapy
- intensive care unit
- emergency department
- stem cells
- bone marrow
- peripheral blood
- disease activity
- sickle cell disease
- hematopoietic stem cell
- clinical trial
- mesenchymal stem cells
- ulcerative colitis
- cardiovascular events
- type diabetes
- cardiovascular disease
- randomized controlled trial
- risk factors
- systemic lupus erythematosus
- coronary artery disease
- single molecule
- phase iii
- metastatic renal cell carcinoma
- smoking cessation
- decision making